Fresh analysis reveals that patients who stop using new GLP-1 drugs like Wegovy and Mounjaro tend to recover reduced body mass far faster than those who stop conventional lifestyle plans.
Research printed in a major medical journal points out that while obese individuals often shed about a fifth of their body weight while undergoing treatment, the mass is regained at an estimated rate of 0.8 kg per month once they quit.
"Users purchasing these treatments need to be aware of the risk of rapid weight regain when the treatment concludes," cautioned lead investigator Dr. Susan Jebb.
That rate of regain suggests a return to starting weight within about one and a half years.
Analyzing Treatments
The analysis, which reviewed dozens of trials involving over 9,000 of participants, compared the effects of GLP-1 agonists with older methods.
The team emphasize that individuals who shed pounds through diet and exercise usually experience a slower creep back—perhaps 100 grams monthly—post-intervention.
Understanding the Rapid Regain
Doctors believe the way of the drugs explains the heightened rebound.
The injections copy a natural hormone called glucagon-like peptide-1, which helps regulate hunger.
"Artificially providing GLP-1 concentrations several times higher than the body's typical production might result in the body to produce less of its endogenous hormone, and may also diminish sensitivity to its effects," explained Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this GLP-1 'fix' leads to hunger is uncontrolled, making binge eating far more likely."
An Ongoing Disease?
The NHS advise the jabs for people with obesity-related health risks, alongside recommended diet and exercise modifications.
Many experts contend that, considering the high risk of relapse, the treatment is often life-long.
This perspective is reinforced by drug manufacturers, who state that the results "highlight the long-term nature of excess weight," similar to managing conditions like diabetes.
User Accounts
People who have discontinued the jabs describe a intense resurgence of appetite.
"I experienced a switch activating and you're instantly starving," said a patient.
The struggle is compounded if patients have not established permanent dietary or behavioural changes during therapy.
Widespread Interest
Survey data indicate that millions of adults in the UK have tried these injections in the last 12 months, with desire remaining high.
- Use is higher among females compared to men.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion obtain the medications through private healthcare rather than the NHS.
In conclusion, researchers caution that while GLP-1 drugs are powerful agents for shedding pounds, they are not a standalone cure and maintained weight loss hinges on integrated behavioural changes.
